Released Jun 29, 2022, after the close
10-K filed Jun 29, 2022, 90 days after period end · 0001493152-22-018108
Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$7.67M$7.67M derived+74.5% vs Q4 2021−14.5% vs Q3 2022
Net Income$2.43M$2.43M derivedN/M vs Q4 2021+6.4% vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$3,456,014+85.2%
Operating Incomederived$851,675N/M
Operating Cash Flowderived$1,605,336N/M
Margins · derived
Gross margin45.0%+2.6 pt vs Q4 2021
Operating margin11.1%+35.4 pt vs Q4 2021
Net margin31.7%+42.6 pt vs Q4 2021
What the release said
The release
Same quarter
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures |
|---|---|---|---|---|
| Revenue | $7.67M | $4.40M | $4.95M | $1.34M |
| Net Income | $2.43M | -$482.62K | $936.37K | -$2.66M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Elite Pharmaceuticals Inc · CIK 1053369 · Engraved from SEC EDGAR